Sales figures for Abstral presented in a press release in Europe

“Abstral’s sales growth is very strong in Europe and we can see that there is a large medical need to be met for cancer patients suffering from breakthrough pain. The increasing royalties are important in developing Orexo into a profitable pharmaceutical company.”

Orexo AB (STO:ORX) announces today that its partner ProStrakan Group plc (LSE:PSK) has presented its sales figures for Abstral in Europe in a press release. ProStrakan states that sales of Abstral underwent a strong development in 2009 and sales in the range of GBP 5 M – GBP 6 M were achieved for full-year. In ProStrakan’s press release from November 2009, it was stated that sales for the first ten months of 2009 amounted to GBP 3.2 M.

Commenting on today’s announcement, Torbjörn Bjerke, Orexo’s President and CEO, said: “Abstral’s sales growth is very strong in Europe and we can see that there is a large medical need to be met for cancer patients suffering from breakthrough pain. The increasing royalties are important in developing Orexo into a profitable pharmaceutical company.”